NYSE:JNJ - Johnson & Johnson Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$121.47 +0.12 (+0.10 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$121.47
Today's Range$121.13 - $122.80
52-Week Range$121.13 - $148.32
Volume4.59 million shs
Average Volume6.04 million shs
Market Capitalization$327.98 billion
P/E Ratio16.64
Dividend Yield2.75%
Beta0.74

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:JNJ
CUSIP47816010
Phone732-524-0400

Debt

Debt-to-Equity Ratio0.47
Current Ratio1.58
Quick Ratio1.25

Price-To-Earnings

Trailing P/E Ratio16.64
Forward P/E Ratio14.94
P/E Growth1.87

Sales & Book Value

Annual Sales$76.45 billion
Price / Sales4.26
Cash Flow$9.4973 per share
Price / Cash12.79
Book Value$23.58 per share
Price / Book5.15

Profitability

EPS (Most Recent Fiscal Year)$7.30
Net Income$1.30 billion
Net Margins1.58%
Return on Equity30.65%
Return on Assets13.26%

Miscellaneous

Employees134,000
Outstanding Shares2,682,900,000

Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Thursday, April 26th. Investors of record on Tuesday, May 29th will be given a dividend of $0.90 per share on Tuesday, June 12th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date is Friday, May 25th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $0.84. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) announced its quarterly earnings data on Tuesday, April, 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion for the quarter, compared to analyst estimates of $19.50 billion. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. Johnson & Johnson's quarterly revenue was up 12.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.83 earnings per share. View Johnson & Johnson's Earnings History.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July, 17th 2018. View Earnings Estimates for Johnson & Johnson.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson updated its FY18 earnings guidance on Tuesday, April, 17th. The company provided earnings per share (EPS) guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.10. The company issued revenue guidance of $81.0-81.8 billion, compared to the consensus revenue estimate of $81.18 billion.

What price target have analysts set for JNJ?

20 equities research analysts have issued 12 month price targets for Johnson & Johnson's shares. Their predictions range from $110.00 to $165.00. On average, they anticipate Johnson & Johnson's stock price to reach $143.0556 in the next year. View Analyst Ratings for Johnson & Johnson.

What are Wall Street analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:
  • 1. According to Zacks Investment Research, "J&J’s sales growth accelerated in the second half of 2017 backed by higher sales in the Pharmaceutical segment and improving performance in Medical Devices. Though quite a few key products in J&J’s portfolio like Remicade and Concerta are facing generic competition, we believe that new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions - mainly Actelion – can support top-line growth. Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. However, headwinds like generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern. J&J’s shares have underformed the industry in this year so far. Estimates have risen slightly ahead of Q1 results. J&J has a positive record of earnings surprises in the recent quarters." (4/16/2018)
  • 2. BTIG Research analysts commented, "Present – Starting to Outweigh Macro Tailwinds On Tuesday before market-open, JNJ reported 4Q17 financial results. In- line with our forecasting for the Pharma segment, the Actelion portfolio has begun to significantly disappoint expectations, Remicade erosion is accelerating, and mainstay franchises such as Imbruvica are beginning to moderate growth. The major discussion point we have had with investors is whether our negative Pharma thesis can trump the positive macro factors. We continue to think so, despite tailwinds such as tax reform helping the stock and overall stock market during 2H2017. At the end of the day, Pharma drives over 50% of total profit generation for the company. We reiterate our Sell rating and $110 PT.   We forecast 1Q18 as the peak of recent Pharma growth and expect a mirror image of 2017 for the remainder of the year, whereby growth will moderate significantly into 2H2018: Our forecast calls for Pharma operational growth of +9.2%/ 6.3%/ 5.1%/ 4.3% during 1Q – 4Q2018, and we now explicitly include the approval of apalutamide within our forecasts (drug model inside report).   Remicade erosion starting to become impactful and deteriorating pricing is likely affecting overall company gross margins: Mgmt noted that volumes for Remicade were generally steady during 4Q17, but this has come at the expense of pricing declines, which is a pure hit to product margins. Our best estimate is that the price erosion of Remicade negatively impacted overall company gross margins by – 30bps YoY during 4Q17." (1/24/2018)

Who are some of Johnson & Johnson's key competitors?

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:
  • Mr. Alex Gorsky, Chairman & CEO (Age 58)
  • Mr. Dominic J. Caruso, Exec. VP & CFO (Age 60)
  • Dr. Paulus A. Stoffels, Exec. VP & Chief Scientific Officer (Age 56)
  • Mr. Joaquin Duato, Exec. VP & Worldwide Chairman of Pharmaceuticals (Age 55)
  • Ms. Sandra E. Peterson, Exec. VP & Group Worldwide Chairman (Age 59)

Has Johnson & Johnson been receiving favorable news coverage?

Press coverage about JNJ stock has been trending somewhat positive on Saturday, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Johnson & Johnson earned a news impact score of 0.12 on Accern's scale. They also assigned press coverage about the company an impact score of 46.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.54%), Northern Trust Corp (1.28%), Massachusetts Financial Services Co. MA (1.11%), Legal & General Group Plc (0.49%), Boston Partners (0.48%) and Fisher Asset Management LLC (0.47%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Which institutional investors are selling Johnson & Johnson stock?

JNJ stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Swiss National Bank, Legal & General Group Plc, Northern Trust Corp, FIL Ltd, Prudential Financial Inc., Barrow Hanley Mewhinney & Strauss LLC and California Public Employees Retirement System. Company insiders that have sold Johnson & Johnson company stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.

Which institutional investors are buying Johnson & Johnson stock?

JNJ stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Boston Partners, Summit Trail Advisors LLC, Flossbach Von Storch AG, Mackay Shields LLC, Schwartz Investment Counsel Inc., The Manufacturers Life Insurance Company and Thrivent Financial for Lutherans. View Insider Buying and Selling for Johnson & Johnson.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $121.47.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $327.98 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $7.30 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.


MarketBeat Community Rating for Johnson & Johnson (JNJ)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  555 (Vote Outperform)
Underperform Votes:  666 (Vote Underperform)
Total Votes:  1,221
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Johnson & Johnson (NYSE:JNJ) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Johnson & Johnson in the last 12 months. Their average twelve-month price target is $143.0556, suggesting that the stock has a possible upside of 17.77%. The high price target for JNJ is $165.00 and the low price target for JNJ is $110.00. There are currently 4 sell ratings, 6 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.302.302.262.35
Ratings Breakdown: 4 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $143.0556$143.0556$145.7222$143.7895
Price Target Upside: 17.77% upside12.86% upside2.74% upside0.98% upside

Johnson & Johnson (NYSE:JNJ) Consensus Price Target History

Price Target History for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/23/2018CitigroupLower Price TargetNeutral$146.00 ➝ $134.00LowView Rating Details
4/20/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$154.00 ➝ $151.00LowView Rating Details
4/18/2018Wells Fargo & CoReiterated RatingOutperform$160.00 ➝ $150.00HighView Rating Details
4/18/2018Stifel NicolausLower Price TargetHold ➝ Hold$145.00 ➝ $135.00HighView Rating Details
4/18/2018Leerink SwannReiterated RatingOutperform$175.00 ➝ $160.00HighView Rating Details
4/18/2018Deutsche BankReiterated RatingBuyHighView Rating Details
4/17/2018Goldman Sachs GroupSet Price TargetSell$134.00LowView Rating Details
4/13/2018Jefferies GroupSet Price TargetBuy$153.00LowView Rating Details
4/10/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$148.00 ➝ $143.00LowView Rating Details
1/24/2018BTIG ResearchReiterated RatingSell$110.00LowView Rating Details
1/9/2018Royal Bank of CanadaReiterated RatingBuyLowView Rating Details
1/2/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLowView Rating Details
12/12/2017BMO Capital MarketsBoost Price TargetOutperform$161.00MediumView Rating Details
10/18/2017BarclaysBoost Price TargetEqual Weight$140.00 ➝ $148.00N/AView Rating Details
10/18/2017CowenReiterated RatingOutperform$147.00 ➝ $155.00N/AView Rating Details
10/18/2017ArgusBoost Price TargetBuy ➝ Positive$145.00 ➝ $165.00N/AView Rating Details
10/4/2017Piper Jaffray CompaniesReiterated RatingHold$120.00LowView Rating Details
9/30/2017UBSReiterated RatingBuy$148.00LowView Rating Details
7/21/2017Alembic Global AdvisorsDowngradeNeutral ➝ UnderweightLowView Rating Details
7/21/2017Atlantic SecuritiesDowngradeNeutral ➝ Underweight$113.00LowView Rating Details
11/28/2016Bank of AmericaReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Johnson & Johnson (NYSE:JNJ) Earnings History and Estimates Chart

Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Earnings Estimates

2018 EPS Consensus Estimate: $8.08
2019 EPS Consensus Estimate: $8.64
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$1.99$2.00$2.00
Q2 20181$2.06$2.06$2.06
Q3 20181$2.02$2.02$2.02
Q4 20181$2.00$2.00$2.00
Q1 20191$2.27$2.27$2.27
Q2 20191$2.17$2.17$2.17
Q3 20191$2.12$2.12$2.12
Q4 20191$2.08$2.08$2.08

Johnson & Johnson (NYSE JNJ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/17/2018$2.06N/AView Earnings Details
4/17/2018Q1 2018$2.00$2.06$19.4975 billion$20.0090 billionViewN/AView Earnings Details
1/23/2018Q4 2017$1.72$1.74$20.0797 billion$20.1950 billionViewListenView Earnings Details
10/17/2017Q3 2017$1.80$1.90$19.2910 billion$19.65 billionViewN/AView Earnings Details
7/18/2017Q2 2017$1.79$1.83$18.9418 billion$18.8390 billionViewN/AView Earnings Details
4/18/2017Q1 17$1.77$1.83$18.0198 billion$17.7660 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.3077 billion$17.3740 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.4139 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
10/19/2010Q3 2010$1.15$1.23ViewN/AView Earnings Details
7/20/2010Q2 2010$1.21$1.21ViewN/AView Earnings Details
4/20/2010Q1 2010$1.27$1.29ViewN/AView Earnings Details
1/26/2010Q4 2009$0.97$1.02ViewN/AView Earnings Details
10/13/2009Q3 2009$1.13$1.20ViewN/AView Earnings Details
7/14/2009Q2 2009$1.12$1.15ViewN/AView Earnings Details
4/14/2009Q1 2009$1.21$1.26ViewN/AView Earnings Details
1/20/2009Q4 2008$0.92$0.94ViewN/AView Earnings Details
10/14/2008Q3 2008$1.11$1.17ViewN/AView Earnings Details
7/15/2008Q2 2008$1.13$1.18ViewN/AView Earnings Details
4/15/2008Q1 2008$1.20$1.26ViewN/AView Earnings Details
1/22/2008Q4 2007$0.86$0.88ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Johnson & Johnson (NYSE:JNJ) Dividend Information

Johnson & Johnson pays an annual dividend of $3.36 per share, with a dividend yield of 2.77%. JNJ's next quarterly dividend payment will be made on Tuesday, June 12. The company has grown its dividend for the last 55 consecutive years and is increasing its dividend by an average of 6.40% each year. Johnson & Johnson pays out 46.03% of its earnings out as a dividend.
Next Dividend:6/12/2018
Annual Dividend:$3.36
Dividend Yield:2.77%
Dividend Growth:6.40% (3 Year Average)
Payout Ratio(s):46.03% (Trailing 12 Months of Earnings)
41.33% (Based on This Year's Estimates)
38.89% (Based on Next Year's Estimates)
35.38% (Based on Cash Flow)
Track Record:55 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/26/2018quarterly$0.902.81%5/25/20185/29/20186/12/2018
1/2/2018quarterly$0.842.39%2/26/20182/27/20183/13/2018
10/19/2017quarterly$0.842.37%11/27/201711/28/201712/12/2017
7/17/2017quarterly$0.842.5%8/25/20178/29/20179/12/2017
4/27/2017quarterly$0.842.72%5/25/20175/30/20176/13/2017
1/3/2017quarterly$0.802.77%2/24/20172/28/20173/14/2017
10/20/2016quarterly$0.8011/18/201611/22/201612/6/2016
7/18/2016quarterly$0.808/19/20168/23/20169/6/2016
4/28/2016quarterly$0.805/20/20165/24/20166/7/2016
1/4/2016quarterly$0.752/19/20162/23/20163/8/2016
10/22/2015quarterly$0.7511/20/201511/24/201512/8/2015
7/20/2015quarterly$0.758/21/20158/25/20159/8/2015
4/23/2015quarterly$0.752.97%5/21/20155/26/20156/9/2015
1/5/2015quarterly$0.702.71%2/20/20152/24/20153/10/2015
10/16/2014quarterly$0.702.89%11/21/201411/25/201412/9/2014
7/21/2014quarterly$0.702.73%8/22/20148/26/20149/9/2014
4/24/2014quarterly$0.702.81%5/22/20145/27/20146/10/2014
1/2/2014quarterly$0.662.87%2/21/20142/25/20143/11/2014
10/17/2013quarterly$0.662.88%11/22/201311/26/201312/10/2013
7/15/2013quarterly$0.662.92%8/23/20138/27/20139/10/2013
4/25/2013quarterly$0.663.1%5/23/20135/28/20136/11/2013
1/2/2013quarterly$0.613.45%2/22/20132/26/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Johnson & Johnson (NYSE JNJ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.22%
Institutional Ownership Percentage: 66.16%
Insider Trading History for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Paulus StoffelsVPSell155,342$129.86$20,172,712.12357,906View SEC Filing  
7/24/2017Paulus StoffelsVPSell102,692$133.14$13,672,412.88230,342View SEC Filing  
7/20/2017Dominic J CarusoVPSell82,591$136.72$11,291,841.52226,693View SEC Filing  
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00127,650View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.2526,520View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46157,819View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.3528,660View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.0543,630View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.0028,725View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.8929,682View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00122,543View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.2037,735View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.5220,803View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.0090,294View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.6015,647View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.0088,159View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.2055,427View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Johnson & Johnson (NYSE JNJ) News Headlines

Source:
DateHeadline
You might want to check the expiration date on your sunscreen before you bring it to the beachYou might want to check the expiration date on your sunscreen before you bring it to the beach
finance.yahoo.com - May 26 at 8:04 AM
What Is Geron Corporations Downside Risk?What Is Geron Corporation's Downside Risk?
www.msn.com - May 25 at 8:07 AM
If You Could Only Choose One Stock - Todays Editors PicksIf You Could Only Choose One Stock - Today's Editors' Picks
seekingalpha.com - May 25 at 8:07 AM
J&J Jury Asks Judge to Slap Cancer Warning Label on Baby PowderJ&J Jury Asks Judge to Slap Cancer Warning Label on Baby Powder
finance.yahoo.com - May 25 at 8:07 AM
Jury recommends $25M in Johnson & Johnson lawsuitJury recommends $25M in Johnson & Johnson lawsuit
finance.yahoo.com - May 25 at 8:07 AM
What Is Geron Corporation's Downside Risk?What Is Geron Corporation's Downside Risk?
finance.yahoo.com - May 25 at 8:07 AM
Johnson & Johnson (JNJ) Receives Consensus Recommendation of "Hold" from AnalystsJohnson & Johnson (JNJ) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 25 at 5:20 AM
Novartis Gets Approval for Remicade Biosimilar in EuropeNovartis Gets Approval for Remicade Biosimilar in Europe
www.zacks.com - May 24 at 5:52 PM
Willams-Sonoma, Deutsche Bank and Johnson & Johnson are the Yahoo Finance charts of the day.Willams-Sonoma, Deutsche Bank and Johnson & Johnson are the Yahoo Finance charts of the day.
finance.yahoo.com - May 24 at 5:52 PM
California Jury Delivers $25.75 Million Verdict in Asbestos Case Tying Johnsons Baby Powder to MesotheliomaCalifornia Jury Delivers $25.75 Million Verdict in Asbestos Case Tying Johnson's Baby Powder to Mesothelioma
www.bizjournals.com - May 24 at 5:52 PM
J&J must pay $4 million in punitive damages in latest asbestos cancer trialJ&J must pay $4 million in punitive damages in latest asbestos cancer trial
www.cnbc.com - May 24 at 4:51 PM
Jury awards $25M in Johnson & Johnson baby powder lawsuitJury awards $25M in Johnson & Johnson baby powder lawsuit
marketbeat.com - May 24 at 4:33 PM
Ex-Dividend Alert: Johnson & Johnson Boosted its Dividend by 7.1%; Will Trade Ex-Dividend on May 25, 2018Ex-Dividend Alert: Johnson & Johnson Boosted its Dividend by 7.1%; Will Trade Ex-Dividend on May 25, 2018
finance.yahoo.com - May 24 at 8:07 AM
J&J Loses Second Talc-Asbestos Cancer Trial and Damages May GrowJ&J Loses Second Talc-Asbestos Cancer Trial and Damages May Grow
finance.yahoo.com - May 23 at 5:45 PM
Chinese investors lead another monster round into this early cancer detection companyChinese investors lead another monster round into this early cancer detection company
finance.yahoo.com - May 22 at 8:10 AM
Johnson & Johnson Vision Launches New Corporate WebsiteJohnson & Johnson Vision Launches New Corporate Website
www.prnewswire.com - May 21 at 5:17 PM
Its Not as Bad as It Looks for Johnson & Johnson StockIt's Not as Bad as It Looks for Johnson & Johnson Stock
investorplace.com - May 21 at 5:17 PM
It’s Not as Bad as It Looks for Johnson & Johnson StockIt’s Not as Bad as It Looks for Johnson & Johnson Stock
finance.yahoo.com - May 21 at 5:17 PM
How to Play the Long Side of Johnson & JohnsonHow to Play the Long Side of Johnson & Johnson
finance.yahoo.com - May 21 at 5:17 PM
It’s Not as Bad as It Looks for Johnson & Johnson StockIt’s Not as Bad as It Looks for Johnson & Johnson Stock
investorplace.com - May 21 at 12:33 PM
J&J Gets Rid Of Drug For Alzheimers, But Remains Strong With Oncology BusinessJ&J Gets Rid Of Drug For Alzheimer's, But Remains Strong With Oncology Business
seekingalpha.com - May 21 at 8:07 AM
Todays Research Reports on Trending Tickers: Johnson & Johnson and The Procter & GambleToday's Research Reports on Trending Tickers: Johnson & Johnson and The Procter & Gamble
finance.yahoo.com - May 21 at 8:06 AM
A Look into Roche Holding’s Performance in Q1 2018A Look into Roche Holding’s Performance in Q1 2018
finance.yahoo.com - May 21 at 8:06 AM
ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate CancerERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
www.prnewswire.com - May 18 at 7:30 PM
Macys, Johnson & Johnson and T. Rowe Price are the Yahoo Finance charts of the day.Macy's, Johnson & Johnson and T. Rowe Price are the Yahoo Finance charts of the day.
finance.yahoo.com - May 18 at 6:14 PM
Congos Ebola not an international emergency, can be controlled -WHOCongo's Ebola not an international emergency, can be controlled -WHO
finance.yahoo.com - May 18 at 6:14 PM
Johnson & Johnson to Post FY2022 Earnings of $11.85 Per Share, Leerink Swann Forecasts (JNJ)Johnson & Johnson to Post FY2022 Earnings of $11.85 Per Share, Leerink Swann Forecasts (JNJ)
www.americanbankingnews.com - May 18 at 8:43 AM
Janssen to Present New Data in Urothelial, Haematologic and Prostate Cancers at ASCO 2018, including Best of ASCO SelectionsJanssen to Present New Data in Urothelial, Haematologic and Prostate Cancers at ASCO 2018, including Best of ASCO Selections
www.businesswire.com - May 18 at 8:13 AM
Why J&Js Stock May Plunge 10%Why J&J's Stock May Plunge 10%
finance.yahoo.com - May 18 at 8:13 AM
Zacks: Analysts Expect Johnson & Johnson (JNJ) Will Announce Quarterly Sales of $20.26 BillionZacks: Analysts Expect Johnson & Johnson (JNJ) Will Announce Quarterly Sales of $20.26 Billion
www.americanbankingnews.com - May 18 at 2:00 AM
Jim Cramer Shares His Thoughts On Johnson & Johnson, Nike And MoreJim Cramer Shares His Thoughts On Johnson & Johnson, Nike And More
finance.yahoo.com - May 17 at 7:12 PM
Why Is Johnson & Johnson (JNJ) Down 4.1% Since its Last Earnings Report?Why Is Johnson & Johnson (JNJ) Down 4.1% Since its Last Earnings Report?
finance.yahoo.com - May 17 at 7:12 PM
How To Get Quality In The CoreHow To Get Quality In The Core
finance.yahoo.com - May 17 at 7:12 PM
How Sensitive Is Johnson & Johnson To Its R&D Expense Change?How Sensitive Is Johnson & Johnson To Its R&D Expense Change?
www.forbes.com - May 17 at 3:51 PM
Johnson & Johnson (JNJ) Consumer and Medical Devices Business Review - Brokers Conference TranscriptJohnson & Johnson (JNJ) Consumer and Medical Devices Business Review - Brokers Conference Transcript
seekingalpha.com - May 17 at 8:09 AM
Johnson & Johnson (JNJ) Expected to Announce Earnings of $2.05 Per ShareJohnson & Johnson (JNJ) Expected to Announce Earnings of $2.05 Per Share
www.americanbankingnews.com - May 16 at 9:18 PM
Jobs alert: Johnson & Johnson Institute in Lake Nona ready to hire managersJobs alert: Johnson & Johnson Institute in Lake Nona ready to hire managers
finance.yahoo.com - May 16 at 5:56 PM
J&J CEO warns of unintended consequences of Trumps drug-price reduction planJ&J CEO warns of 'unintended consequences' of Trump's drug-price reduction plan
www.cnbc.com - May 16 at 10:16 AM
Johnson & Johnson to relaunch baby care line after its 20% sales declineJohnson & Johnson to relaunch baby care line after its 20% sales decline
www.msn.com - May 16 at 8:05 AM
What Can I Expect To Make If I Invest In Johnson & Johnson Today?What Can I Expect To Make If I Invest In Johnson & Johnson Today?
seekingalpha.com - May 16 at 8:05 AM
Johnson & Johnson relaunches 124-year-old baby shampoo br...Johnson & Johnson relaunches 124-year-old baby shampoo br...
finance.yahoo.com - May 16 at 8:05 AM
Stocks are set to fall at the open after Dow ends 8-day win streakStocks are set to fall at the open after Dow ends 8-day win streak
finance.yahoo.com - May 16 at 8:05 AM
Johnson & Johnson to relaunch baby-care line after its 20% sales declineJohnson & Johnson to relaunch baby-care line after its 20% sales decline
finance.yahoo.com - May 16 at 8:05 AM
Stocks making the biggest moves premarket: JNJ, SBUX, MMM, CHDN, ABAX, ROKU & moreStocks making the biggest moves premarket: JNJ, SBUX, MMM, CHDN, ABAX, ROKU & more
finance.yahoo.com - May 16 at 8:05 AM
WHO deploys experimental vaccines to fight Ebola outbreak...WHO deploys experimental vaccines to fight Ebola outbreak...
finance.yahoo.com - May 15 at 5:57 PM
Should You Buy Johnson & Johnson (NYSE:JNJ) Now?Should You Buy Johnson & Johnson (NYSE:JNJ) Now?
finance.yahoo.com - May 12 at 8:11 AM
Trump's prescription to reduce drug prices takes small stepsTrump's prescription to reduce drug prices takes small steps
finance.yahoo.com - May 12 at 8:11 AM
Few teeth in Trumps prescription to reduce drug pricesFew teeth in Trump's prescription to reduce drug prices
marketbeat.com - May 11 at 6:30 PM
Johnson & Johnson: Waiting On The WaveJohnson & Johnson: Waiting On The Wave
seekingalpha.com - May 11 at 6:13 PM
NeuClone communique les résultats précliniques du candidat biosimilaire du Stelara® (ustekinumab)NeuClone communique les résultats précliniques du candidat biosimilaire du Stelara® (ustekinumab)
www.prnewswire.com - May 10 at 5:15 AM

SEC Filings

Johnson & Johnson (NYSE:JNJ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Johnson & Johnson (NYSE:JNJ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Johnson & Johnson (NYSE JNJ) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.